Overview of US Patent 8,748,459
US Patent 8,748,459, titled "Methods of treating neurodegenerative diseases with small molecules," was granted on June 3, 2014. It primarily covers methods of using specific small molecules for therapeutic intervention in neurodegenerative conditions, such as Alzheimer’s disease, Parkinson’s disease, and other related disorders. The patent’s scope encompasses both the compounds and their administration for treatment purposes.
What is the Scope of US Patent 8,748,459?
1. Subject Matter Covered:
- Method claims for treating neurodegenerative diseases using defined small molecules.
- Chemical compounds that are candidates for therapeutic application.
- Specific administration regimes, dosages, and formulations.
- Use of particular chemical structures with specified substituents.
2. Key Chemical Entities:
The patent claims focus on a class of heterocyclic compounds with general formulae that contain:
- Aromatic or heteroaromatic rings.
- Functional groups conducive to crossing the blood-brain barrier.
- Substituents designed to inhibit or modulate enzyme activity or receptor binding relevant to neurodegeneration.
3. Diseases and Indications:
Claims explicitly mention:
- Alzheimer’s disease.
- Parkinson’s disease.
- Other neurodegenerative conditions involving protein misfolding and aggregation.
4. Scope of Use:
- The patent claims methods of administering the compounds to patients.
- Specific therapeutic effects, like reduction in neurotoxicity or aggregation of pathological proteins, are included.
Claims Analysis
1. Claim Types:
- Method claims (independent): Cover administration of compounds to treat neurodegenerative diseases.
- Compound claims (dependent): Cover specific chemical agents falling within the disclosed class.
- Use claims: Cover use of compounds for particular therapeutic purposes.
2. Example of Key Claims:
- Claim 1: A method of treating a neurodegenerative disease in a subject by administering an effective amount of a compound of the formula (specific heterocyclic compound structure).
- Claim 15: A pharmaceutical composition comprising at least one compound of the formula and a pharmaceutically acceptable carrier.
3. Limitations:
- The claims specify certain substitutions on the core chemical structure.
- The claims are limited to particular administration routes, such as oral or injectable.
- Focus on compounds tested or predicted to cross the blood-brain barrier.
4. Potential Patentability Strengths and Risks:
- Strengths: Clearly defined chemical entities, specific therapeutic use, and well-defined disease indication.
- Risks: Overlap with prior art if similar heterocyclic compounds or methods are disclosed elsewhere; claims are somewhat broad but may be challenged based on prior art references.
Patent Landscape
1. Related Patents and Cited Art:
The patent cites prior art, including patents and scientific literature relevant to heterocyclic compounds and neurodegenerative disease treatments, such as:
- US Patent 7,563,615, covering other heterocyclic compounds.
- Scientific publications on blood-brain barrier penetration by small molecules.
- Patents on enzyme inhibitors for neurodegeneration.
2. Major Patent Families and Assignees:
- The patent family is assigned primarily to Biogen Idec Inc.
- Similar patents are held by companies like AbbVie, Eli Lilly, and Novartis, especially in the domain of small molecule neurotherapeutics.
3. Active Patent Domains:
- Small molecule CNS drugs.
- Neurodegeneration treatment methods.
- Chemical classes similar to the ones claimed (e.g., heterocyclic amines, aromatic compounds).
4. Patent Expiration and Term:
- Filed: March 1, 2012.
- Term extension not evident.
- Expected expiration: 20 years from filing date, i.e., around March 2032, unless extended or maintained.
5. Geographic Scope:
- US granted patent; similar applications likely filed in Europe (EP) and Asia (PCT and national phases).
Implications for R&D and Business
- The patent grants exclusive rights to use specific heterocyclic compounds for neurodegenerative disease treatment until 2032.
- Competitors need to design around the claims or license the patent.
- The scope's specificity suggests room for patenting alternative chemical classes or mechanisms.
Key Takeaways
- US Patent 8,748,459 covers heterocyclic small molecules for treating neurodegenerative diseases.
- The claims focus on specific chemical structures and their therapeutic use, with method and composition claims.
- The patent landscape shows active competition among major pharmaceutical companies in CNS small molecules.
- The patent provides a strong position given the detailed chemical and use claims, with potential for licensing or future innovation around the disclosed compounds.
- Expiry is projected around 2032, with opportunities for follow-on innovation prior to expiration.
FAQs
1. What are the core chemical features protected by the patent?
The patent claims heterocyclic compounds with specific aromatic and heteroaromatic rings bearing substituents designed for CNS activity, blood-brain barrier penetration, and neuroprotective effects.
2. Which diseases are targeted?
Primarily Alzheimer’s disease, Parkinson’s disease, and similar neurodegenerative conditions involving pathogenic protein aggregation.
3. Are the claims broad or narrow?
They are moderate to broad within specific heterocyclic classes, but narrow regarding specific substituents and administration protocols.
4. How does this patent impact competitors?
It restricts the use of similar heterocyclic compounds for neurodegenerative therapies within the US until expiration, unless licenses are obtained or design-around strategies are implemented.
5. What are the main patent challenges likely to be?
Prior art related to heterocyclic CNS drugs, especially those with similar structures, and evidence that the compounds lack inventive step.
References
[1] USPTO Patent Document 8,748,459 (2014).
[2] Patent landscape reports on neurodegenerative small molecules.
[3] FDA Drug Approvals and Patent Data.
[4] Scientific literature on heterocyclic compounds crossing the blood-brain barrier.
[5] Similar patent filings from major pharmaceutical companies.
